Fan Lei, Miao Yi, Wu Yu-Jie, Wang Yan, Guo Rui, Wang Li, Shen An-Li, Chen Yao-Yu, Xu Wei, Li Jian-Yong
a Department of Hematology , the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital , Nanjing , China.
Leuk Lymphoma. 2015;56(12):3329-35. doi: 10.3109/10428194.2015.1030642. Epub 2015 Jun 19.
Different combinations of biomarkers analyzed by flow cytometry are critical for the accurate diagnosis of leukemic B-cell chronic lymphoproliferative disorders (B-CLPDs). We investigated CD200 and CD148 expression patterns of blood or bone marrow from 374 cases of B-CLPD by multicolor flow cytometry. Our results showed that CD200 and CD148 expression patterns distinguished different types of B-CLPD. CD200 mean fluorescence intensity (MFI) or CD148 MFI had a high sensitivity and specificity to differentiate mantle cell lymphoma (MCL) from chronic lymphocytic leukemia (CLL). Furthermore, CD148 MFI/CD200 MFI ratio>4.79 produced a specificity of 94.46% (95% confidence interval [CI]: 91.04-96.87%) and a sensitivity of 100% (95% CI: 88.78-100.0%) in establishing the diagnosis of MCL in differential diagnosis between MCL and CLL. We therefore conclude that the combination of CD200 and CD148 may have a potential differential diagnostic value in leukemic B-CLPDs, especially between CLL and MCL.
通过流式细胞术分析的不同生物标志物组合对于白血病性B细胞慢性淋巴细胞增殖性疾病(B-CLPD)的准确诊断至关重要。我们采用多色流式细胞术研究了374例B-CLPD患者血液或骨髓中CD200和CD148的表达模式。我们的结果表明,CD200和CD148的表达模式可区分不同类型的B-CLPD。CD200平均荧光强度(MFI)或CD148 MFI对区分套细胞淋巴瘤(MCL)与慢性淋巴细胞白血病(CLL)具有高敏感性和特异性。此外,在MCL与CLL的鉴别诊断中,CD148 MFI/CD200 MFI比值>4.79诊断MCL的特异性为94.46%(95%置信区间[CI]:91.04-96.87%),敏感性为100%(95%CI:88.78-100.0%)。因此,我们得出结论,CD200和CD148的组合在白血病性B-CLPD中,尤其是在CLL和MCL之间,可能具有潜在的鉴别诊断价值。